Form 4: Electromed Director Sells Shares Under 10b5-1 Plan

Electromed Director Andrew Summers sold a total of 65,654 shares of common stock across two days in September 2025, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Andrew Summers, a Director of Electromed, Inc. (ELMD), reported the sale of common stock.
• On September 10, 2025, Mr. Summers sold 39,378 shares at a weighted average price of $23.6791 per share, with prices ranging from $23.52 to $24.51.
• Also on September 10, 2025, he sold 16,203 shares at a weighted average price of $25.159 per share, with prices ranging from $24.52 to $25.51.
• Further sales on September 10, 2025, included 6,576 shares at $25.9443 (range $25.515-$26.50) and 404 shares at $26.6246 (range $26.525-$26.635).
• On September 11, 2025, an additional 3,153 shares were sold at a weighted average price of $24.4214 per share, with prices ranging from $24.39 to $24.46.
• All reported transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• Following these transactions, Mr. Summers directly owns 9,000 shares of Common Stock.
• Indirect beneficial ownership includes 26,336 shares through SVP Deal Fund I LP, 10,133 shares through SPV Deal Fund I LP, 3,557 shares through SPV Deal Fund I LP, 3,153 shares through SVP Deal Fund I LP (now 0 after the 09/11/2025 sale), and 270,267 shares through Summers Value Fund LP.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly negative. While it's an insider sale, the disclosure of a 10b5-1 plan mitigates the negative perception significantly, as it indicates the sales were pre-planned and not reactive to new, non-public information. However, it still represents a reduction in insider ownership.

Positives

• The sales were conducted under a Rule 10b5-1(c) plan, indicating they were pre-scheduled and not based on new, non-public information, which mitigates concerns about insider selling.

Negatives

• A director reducing their direct and indirect holdings, even under a 10b5-1 plan, represents a decrease in insider ownership and could be perceived by some investors as a lack of increased conviction in the company's future prospects.

Risks

• Potential for negative market sentiment if investors misinterpret the insider sales as a signal of deteriorating company performance, despite the 10b5-1 plan.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing pertains to an individual insider transaction and does not provide broader industry trends or competitive analysis. It reflects a director's personal portfolio management decisions.

Related Party Transactions

• Andrew Summers indirectly beneficially owns securities through SVP Deal Fund I LP and Summers Value Fund LP, where he serves as a Managing Member of the general partner and investment manager, respectively. He disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders may interpret the director's sale as a signal, potentially leading to short-term negative sentiment, although the 10b5-1 plan should temper such reactions.

Key Dates

Recommendation

The director's sale of shares was conducted under a pre-arranged 10b5-1 trading plan. This indicates the transactions were scheduled in advance and not based on recent, non-public information. While a reduction in insider ownership can sometimes be a concern, the existence of a 10b5-1 plan suggests a planned portfolio adjustment rather than a reaction to adverse company developments. Therefore, without additional information, this filing alone does not warrant a change from a 'hold' recommendation, but investors should monitor future company performance and other insider activity.

Keywords

Electromed, ELMD, Form 4, Insider Sale, Andrew Summers, Director, Stock Transaction, 10b5-1 Plan, Beneficial Ownership